This is the authors' abstract. We don't add key points for this paper.
Objective: Osteosarcoma is a rare primary bone cancer of adolescents and young adults without significant improvement in treatments or outcomes in several decades. Resection is standard of care for recurrent disease. Patients with lung only osteosarcoma recurrence following surgical resection (LOOR-FSR) may present the most meaningful opportunity for impactful intervention but alternative trial endpoints to objective response are needed. Here we update benchmarks for LOOR-FSR with contemporary clinical trial data. Patients/Methods: This study included patients with pathologically confirmed LOOR-FSR enrolled on three Childrens Oncology Group phase 2 single arm trials. Benchmark endpoints assessed in this patient population were event-free survival (EFS) and overall survival (OS). In addition, we evaluated the impact of demographics and baseline clinical factors on outcome. Results: Ninety-nine patients met criteria for inclusion in this analysis. Median EFS and OS were 4.8 (95% CI: 3.5, 6.3) and 26.2 (23.3, 56.8) months respectively. Twelve-month EFS was 22% (15-31%) and ranged from 14% to 29% across the 3 trials, a difference that did not achieve statistical significance. The risk of EFS event was higher for those whose first recurrence occurred within two years of diagnosis (p=0.009). Other demographic and clinical factors did not statistically impact risk of event though estimated EFS for males was lower than for females. Conclusion: Despite almost doubling the number of patients in this historical control cohort, wide variance in outcomes led to confidence intervals unchanged from previously published work. Until the most significant factors contributing to variability of outcomes in this patient population are quantified, single arm trials of new approaches will only be able to identify large effect sizes. Smaller effect sizes will require randomization.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chou et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: